Literature DB >> 10737388

Absence of telomerase activity and telemorase catalytic subunit mRNA in melanocyte cultures.

K Dhaene1, G Vancoillie, J Lambert, J M Naeyaert, E Van Marck.   

Abstract

The classic model of activation of telomerase, for which activity has been found in most cancers including cutaneous malignant melanoma (CMM), dictates that enzyme activity is generated by pathological reactivation of telomerase in telomerase-negative somatic cells. However, recent data demonstrated physiological up-regulation in some normal cell types when established as proliferating cultures, indicating that, in some cancer types, telomerase is expressed by the process of up-regulation in telomerase-competent precursor cells. In this study, cultures of epidermal melanocytes, progenitor cells of CMM, were established and harvested in the logarithmic phase of growth. Telomerase activity was looked for using a non-isotopic variant of the telomeric repeat amplification protocol, and transcript expression of the hTERT gene, the rate-limiting catalytic telomerase subunit, was investigated by the reverse transcription polymerase chain reaction. Neither telomerase activity nor hTERT mRNA could be detected in proliferating melanocyte cultures. Our in vitro data argue against the model of telomerase as a common biomarker of cell proliferation. The results further suggest that telomerase is tightly controlled in normal melanocytes, and that telomerase is reactivated rather than up-regulated in melanocytic precursors during melanoma initiation or progression.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10737388      PMCID: PMC2374429          DOI: 10.1054/bjoc.1999.1041

Source DB:  PubMed          Journal:  Br J Cancer        ISSN: 0007-0920            Impact factor:   7.640


  53 in total

1.  Telomerase catalytic subunit homologs from fission yeast and human.

Authors:  T M Nakamura; G B Morin; K B Chapman; S L Weinrich; W H Andrews; J Lingner; C B Harley; T R Cech
Journal:  Science       Date:  1997-08-15       Impact factor: 47.728

2.  Regulation of telomerase activity in immortal cell lines.

Authors:  S E Holt; W E Wright; J W Shay
Journal:  Mol Cell Biol       Date:  1996-06       Impact factor: 4.272

3.  Lack of cell cycle regulation of telomerase activity in human cells.

Authors:  S E Holt; D L Aisner; J W Shay; W E Wright
Journal:  Proc Natl Acad Sci U S A       Date:  1997-09-30       Impact factor: 11.205

Review 4.  Telomerase activity, cell proliferation, and cancer.

Authors:  C W Greider
Journal:  Proc Natl Acad Sci U S A       Date:  1998-01-06       Impact factor: 11.205

5.  Up-regulation of telomerase activity in human lymphocytes.

Authors:  O Yamada; T Motoji; H Mizoguchi
Journal:  Biochim Biophys Acta       Date:  1996-12-12

6.  Evidence for UV-associated activation of telomerase in human skin.

Authors:  M Ueda; A Ouhtit; T Bito; K Nakazawa; J Lübbe; M Ichihashi; H Yamasaki; H Nakazawa
Journal:  Cancer Res       Date:  1997-02-01       Impact factor: 12.701

7.  Chromosome end-to-end associations and telomerase activity during cancer progression in human cells after treatment with alpha-particles simulating radon progeny.

Authors:  T K Pandita; E J Hall; T K Hei; M A Piatyszek; W E Wright; C Q Piao; R K Pandita; J C Willey; C R Geard; M B Kastan; J W Shay
Journal:  Oncogene       Date:  1996-10-03       Impact factor: 9.867

Review 8.  Telomere structure and telomerase expression during mouse development and tumorigenesis.

Authors:  D Kipling
Journal:  Eur J Cancer       Date:  1997-04       Impact factor: 9.162

9.  A mammalian telomerase-associated protein.

Authors:  L Harrington; T McPhail; V Mar; W Zhou; R Oulton; M B Bass; I Arruda; M O Robinson
Journal:  Science       Date:  1997-02-14       Impact factor: 47.728

10.  Telomerase activity: a biomarker of cell proliferation, not malignant transformation.

Authors:  C D Belair; T R Yeager; P M Lopez; C A Reznikoff
Journal:  Proc Natl Acad Sci U S A       Date:  1997-12-09       Impact factor: 11.205

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.